Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.

Part of paid clinical trials in Miami, Florida.

Sponsor
Bernard (Barry) Baumel
Study ID
NCT06781333
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
55 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • hMSC — BIOLOGICAL
    Participants will come in person to receive one intravenous infusion of approximately 25 million cells up to 20 minutes.

Study Details

The purpose of this research study is to test if adding one infusion of mesenchymal stem cells to the current treatment with antipsychotic medication may help control behavioral problems in people with a diagnosis of moderate to severe Alzheimer's disease.

Key Dates

Start date
Apr 29, 2025
Status verified
May 2026
Primary completion
Dec 15, 2027
Completion
Dec 15, 2027

Study Design

Enrollment
8 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: hMSC group
    Participants in this group will receive one infusion of hMSC. Total participation is up to 12 weeks.

Primary Outcome Measure

Neuropsychiatric Inventory [ Time Frame: Up to 12 weeks. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Miami Department of NeurologyMiamiFlorida33136
Maria E. Puertas
[email protected]
(305) 243-0184
Carmen Perez
[email protected]
(305) 243-0184
Bernard S. Baumel, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Miami, FL

By condition
Alzheimer's disease
By specialty
NeurologyDementia careBrain disordersGeriatrics
By research site
University of Miami Department of Neurology· Miami, FL

Related Studies